Bristol Myers Squibb reports successful trial for myeloma treatment
必治妥施貴寶報告骨髓瘤治療試驗取得成功
更新於: 2026年9月26日 上午02:50
Bristol Myers Squibb (BMS) is making significant strides in the fight against multiple myeloma, a complex blood cancer. The company recently shared promising data from several clinical trials, highlighting a strategic shift toward next-generation therapies. Central to this progress is ZENBEXUS™ (iberdomide), a novel CELMoD agent. In the Phase 3 EXCALIBER-RRMM trial, patients using a regimen containing ZENBEXUS showed much better clinical outcomes compared to standard treatments. The U.S. FDA recently granted accelerated approval for this regimen, marking a major milestone for patients who have already undergone prior therapy. Beyond small-molecule drugs like ZENBEXUS and mezigdomide, BMS is advancing its cell therapy pipeline. The Phase 2 QUINTESSENTIAL trial revealed that its investigational CAR T-cell therapy, arlo-cel, achieved strong response rates in patients who were previously resistant to other treatments. By targeting GPRC5D, arlo-cel offers a new path for those who have exhausted existing options. As revenue from older medications declines due to generic competition, these innovative treatments are essential to the company’s future. Through both CELMoD platforms and sophisticated CAR T technology, BMS is successfully refreshing its hematology portfolio to tackle treatment resistance.
百時美施貴寶(Bristol Myers Squibb, BMS)在對抗多發性骨髓瘤(multiple myeloma)這項複雜的血癌上,正取得重大進展。該公司近期分享了來自多項臨床試驗的樂觀數據,突顯出其向次世代療法轉型的策略。這項進展的核心是ZENBEXUS™(iberdomide),這是一種新型的CELMoD製劑。在第3期EXCALIBER-RRMM試驗中,使用含ZENBEXUS治療方案的病患,其臨床成效較標準療法有顯著提升。美國食品藥物管理局(FDA)近期給予該方案加速核准,對先前已接受過治療的患者而言,是一個重要的里程碑。除了像ZENBEXUS和mezigdomide這類小分子藥物外,BMS也在推進其細胞療法管線。第2期QUINTESSENTIAL試驗顯示,其研發中的CAR T細胞療法arlo-cel,在先前對其他療法產生抗藥性的患者中,達成了強勁的反應率。透過標靶GPRC5D,arlo-cel為那些已窮盡現有治療選項的患者提供了新的出路。隨著舊藥因學名藥競爭而導致營收下滑,這些創新療法對該公司的未來至關重要。透過CELMoD平台與精密複雜的CAR T技術,BMS成功地更新了其血液科產品組合,以應對治療抗藥性。
